Back to top

Here's Why Momentum Investors Will Love Sesen Bio (SESN)

Read MoreHide Full Article

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Sesen Bio (SESN - Free Report) , which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Sesen Bio currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

You can see the current list of Zacks # 1 Rank Stocks here >>>

Set to Beat the Market?

In order to see if SESN is a promising momentum pick, let's examine some Momentum Style elements to see if this biopharmaceutical company holds up.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For SESN, shares are up 26.55% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 3.09% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 48.75% compares favorably with the industry's 3.36% performance as well.

Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Over the past quarter, shares of Sesen Bio have risen 6.25%, and are up 112.5% in the last year. In comparison, the S&P 500 has only moved 5.93% and 19.01%, respectively.

Investors should also pay attention to SESN's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. SESN is currently averaging 1,114,046 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score looks at estimate revision trends as well as price changes, though investors should also note that any direction in estimate revisions remains key to the Zacks Rank. A nice path here can be promising, and we have recently been noticing that with SESN.

Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. These revisions helped boost SESN's consensus estimate, increasing from -$0.48 to -$0.39 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.

Bottom Line

Given these factors, it shouldn't be surprising that SESN is a #2 (Buy) stock and boasts a Momentum Score of B. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Sesen Bio on your short list.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Eleven Biotherapeutics, Inc. (SESN) - free report >>

More from Zacks Tale of the Tape

You May Like